CCCC250117P1000
- 0.00
- 0.000.00%
C4 Therapeutics Newsroom
C4 Therapeutics Gains After Portfolio Updates
Express News | C4 Therapeutics: Cash Runway Expected to Fund Operations Into 2027
Express News | C4 Therapeutics: Data in Melanoma & Colorectal Cancer Expected in Second Half of 2025
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?
Wells Fargo Upgrades C4 Therapeutics(CCCC.US) to Buy Rating, Raises Target Price to $12
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday
Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12
Innate IPHA Phase 2 Data; C4 Therapeutics CCCC Phase 1 ASH Data
C4 Therapeutics Stock Surges on Positive Early Cancer Trial Results
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting That Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 34% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Press Release: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Stephens & Co. Initiates Coverage On C4 Therapeutics With Equal-Weight Rating, Announces Price Target of $4
C4 Therapeutics Analyst Ratings
Express News | C4 Therapeutics Inc Files for Stock Shelf Offering of up to $200 Mln - SEC Filing
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14